CAS No.: 123663-49-0
Category: Disease-Modifying Antirheumatic Drug (DMARD)
Synonyms: T-614, IGU
Molecular Formula: C₁₇H₁₄N₂O₆S
Molecular Weight: 374.37 g/mol
Iguratimod is a synthetic small-molecule conventional disease-modifying antirheumatic drug (csDMARD) with immunomodulatory and anti-inflammatory properties. It has been developed primarily for the treatment of rheumatoid arthritis (RA) and is used clinically in Japan and China.
Iguratimod acts on several inflammatory and immune pathways involved in rheumatoid arthritis. It can suppress the production of pro-inflammatory cytokines, reduce immunoglobulin and autoantibody production by B cells, and modulate NF-κB signaling. Research also indicates effects on osteoclast activity and bone formation, contributing to its potential joint-protective effects.
Chemical name: N-[7-(methanesulfonamido)-4-oxo-6-phenoxychromen-3-yl]formamide.
Iguratimod is primarily associated with rheumatology and autoimmune disease research, particularly rheumatoid arthritis.
Iguratimod is a pharmacologically active immunomodulatory compound and should be handled according to the applicable SDS, occupational safety procedures and regulatory requirements.
For pharmaceutical/API applications, material should be handled under appropriate GMP, quality-control and containment procedures.
Iguratimod has clinically relevant safety considerations, including reported liver enzyme elevations and thrombocytopenia, so pharmaceutical use requires appropriate medical supervision and monitoring.
Iguratimod has a multifactorial immunomodulatory and anti-inflammatory mechanism rather than acting through a single target.
Iguratimod inhibits activation of the NF-κB signaling pathway, including inhibition of NF-κB p65 phosphorylation and nuclear translocation. NF-κB regulates the expression of numerous inflammatory mediators.
Iguratimod reduces production of inflammatory cytokines such as:
This contributes to suppression of inflammatory activity in rheumatoid arthritis.
Iguratimod suppresses the differentiation of B cells into antibody-secreting cells and reduces production of immunoglobulins and autoantibodies. This is particularly relevant because B-cell-derived antibodies contribute to autoimmune inflammation in RA.
Iguratimod modulates T-cell-mediated immune responses and can influence inflammatory pathways associated with Th1/Th17 activity.
Research suggests Iguratimod can inhibit osteoclast-mediated bone resorption and promote osteoblast differentiation. It has also been reported to suppress production of matrix metalloproteinases such as MMP-1 and MMP-3, which are involved in cartilage degradation.
Simplified mechanism:
Iguratimod → NF-κB/cytokine pathway modulation → ↓ inflammatory cytokines + ↓ immunoglobulin/autoantibody production → reduced immune-mediated inflammation → potential reduction in joint damage
Iguratimod is a synthetic small-molecule conventional disease-modifying antirheumatic drug (csDMARD) with anti-inflammatory and immunomodulatory activity.
The CAS number of Iguratimod is 123663-49-0.
Its molecular formula is C₁₇H₁₄N₂O₆S.
The molecular weight is 374.37 g/mol.
Iguratimod is primarily used as a DMARD for rheumatoid arthritis and is also investigated for its immunomodulatory and anti-inflammatory effects in other autoimmune and rheumatic diseases.
Iguratimod acts through multiple pathways, including suppression of NF-κB signaling, reduction of inflammatory cytokine production and inhibition of B-cell immunoglobulin production.
Research has reported inhibition of several inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-8 and IL-17.
Yes. Iguratimod can inhibit B-cell differentiation into antibody-secreting cells and reduce production of immunoglobulins and autoantibodies.
Yes. T-614 is a development code/synonym for Iguratimod.
Its IUPAC name is N-[7-(methanesulfonamido)-4-oxo-6-phenoxychromen-3-yl]formamide
R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is a chiral pharmaceutical intermediate associated with the synthesis of Mirabegron. It contains a stereochemically defined hydroxyphenylacetamide structure and a nitrophenethyl
Methyl 2-[4-(4-chlorobutanoyl)phenyl]-2-methylpropanoate is a chlorinated aromatic ketone ester used as a pharmaceutical intermediate in the synthesis of fexofenadine hydrochloride. It provides a
2-Chloromethyl-3,4-dimethoxypyridine hydrochloride is a pyridine-based pharmaceutical intermediate used in the synthesis of pantoprazole sodium. It serves as a chemical building block in
